Arch Therapeutics, Inc. (ARTH) Preparing to Initiate Human Clinical Trials for Innovative Hemostatic Device
Arch Therapeutics is a medical device company developing a novel approach to stopping bleeding and controlling leaking during surgery and trauma care. The company’s leading product candidate, the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures, effectively making surgery faster and safer for patients. Unlike currently available products, AC5 has been shown to promptly stop bleeding by conforming to irregular wound geometry, and, with a completely transparent construction, it allows surgeons to maintain a clear field of vision directly into a wound without hampering future healing. In recent months, Arch has…